Our mouse models of pRCC and ccRCC faithfully recapitulate the genomics of human RCC although the incidence of ccRCC tumours that have coincident VHL and CDKN2A inactivation, along with MYC activation is only ∼6%. This evidence concerns the gene MYC and nonpapillary renal cell carcinoma.